Ripretinib
| CAS No. | 1442472-39-0 | Cat. No. | BCP29218 |
| Name | Ripretinib | ||
| Synonyms | DCC 2618;DCC2618;KIT/PDGFR inhibitor;Ripretinib; | ||
| Formula | C24H21BrFN5O2 | M. Wt | 510.36 |
| Description | Ripretinib, also known as DCC-2618, is a potent, orally active and selective KIT/PDGFR inhibitor with potential antineoplastic activity. DCC-2618 targets and binds to both wild-type and mutant forms of KIT and PDGFRa specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. DCC-2618 also inhibits several other kinases, including vascular endothelial growth factor receptor type 2 (VEGFR2; KDR), angiopoietin-1 receptor (TIE2; TEK), PDGFR-beta and macrophage colony-stimulating factor 1 receptor (FMS; CSF1R), thereby further inhibiting tumor cell growth. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | PDGFR c Kit | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.